Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by fox7mfon Jun 15, 2023 9:18am
193 Views
Post# 35497742

RE:RE:RE:RE:RE:RE:ONC...what's it going to take to break loose!!

RE:RE:RE:RE:RE:RE:ONC...what's it going to take to break loose!!Definitely. OS with Bracelet, updates on PDAC and CRC (ESMO in Oct) is what Oncy is waiting for to get offers way up. A little disheartening that all that is many months away. Everyone remembers MC back in November 2022 exclaiming the next 6-9 months would be the most exciting and consequential in the biotechs history. July is the 9th month, and we continue to languish. Maybe they've received offers on Bracelet data alone. Maybe those offers are $4-$5b. Maybe they expect to triple or more those offers with Goblet and the rest. Again, we're stumbling in the dark.
<< Previous
Bullboard Posts
Next >>